Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
M7824 has anti-tumor efficacy against murine EMT6 breast and MC38 colon ...
M7824 combination with Ad-TWIST improves anti-tumor efficacy versus ...
Our new Immuno-Oncology pipeline asset M7824 is an exciting ...
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein ...
Abstract CT080: Pharmacokinetic and pharmacodynamic analysis of M7824 ...
M7824 induces a more active CD8C T and NK cell phenotype in the TME ...
(PDF) 1463PUpdated results of M7824 (MSB0011359C): A bifunctional ...
M7824 increases CD8C and NK cell numbers in the lymph nodes and ...
Randomized open-label study of M7824 versus pembrolizumab as first-line ...
第二代双靶点药物,双靶点抑制剂,双功能抗体蛋白M7824(Bintrafusp Alfa)客观缓解率高达85.7%-无癌家园
肺癌重磅新药M7824！双功能性免疫疗法，总缓解率高达71.4% - 知乎
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion ...
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation ...
| The structure of the bifunctional fusion protein, M7824. The light ...
(PDF) M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein ...
M7824二線治療PD-L1≥1%非小細胞肺癌客觀緩解率達40.7% - 每日頭條
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824 ...
亦正亦邪的 “双面”靶点：TGF-β|M7824|抑制剂|靶点|肿瘤|细胞|靶向|药物|蛋白|-健康界
Merck KGaA, Darmstadt, Germany and GSK Announce Global Alliance
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein ...
Full article: M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion ...
Full article: A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein ...
默克M7824 PD-L1/TGFβ 双抗卷土从来？|默克|双抗|细胞|抗体|临床|受体|肿瘤|-健康界
PD-L1/TGF-β双抗M7824治疗复发/转移性宫颈癌疗效初现_肿瘤
PD-L1/TGF-β双功能融合蛋白M7824分析，默克能否靠它翻身？|默克|临床|临床试验_新浪新闻
Frontiers | Bispecific antibody targeting TGF-β and PD-L1 for ...
PD-L1、TGFß(TGF贝塔)双靶点抑制剂新药M7824(Bintrafusp Alfa)客观缓解率近90%-无癌家园
Combination therapy tested in clinical trial for metastatic ...
肿瘤免疫治疗的进化！二代PD-1抗体即将出世_PD-1抗体-美迪西生物医药
挑战K药失败！默克终止M7824一线治疗NSCLC III期研究 1月20日， 默克 公布了其潜在first-in-class靶向PD-L1 ...
友芝友生物PD-L1/TGF-β双特异性抗体新药获得美国FDA临床试验批准
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β ...
Bintrafusp alfa (designated in previous publications as M7824) reduces ...
M7824是癌症免疫疗法PD-L1抗体的增强版【康必行海外医疗】
(PDF) Bintrafusp alfa (M7824), a bifunctional fusion protein targeting ...
The structure of bispecific and bifunctional antibodies targeting TGF-b ...
PD-1/L1双抗的主流第二靶点：谁将遭到淘汰？ - 脉脉
Novel Targeted Agents for Lung Cancer: M7824, a Bifunctional Protein ...
PD-L1/TGF-β双功能融合蛋白M7824分析，默克能否靠它翻身？|葛兰素史克|抗体_新浪新闻
Dual-Targeting Approach to Tumor Immunotherapy: Insights into M7824's ...
第二代PD-1抑制剂，总缓解率高达71.4%的双功能性免疫新药M7824 - 每日头条
默克旗下PD-L1/TGF-β双抗M7824获得CDE获得国内受理 - 中国基因网
PD-L1/TGF-β双功能融合蛋白M7824分析，默克能否靠它翻身？
PD-L1/TGF-β双功能融合蛋白M7824分析，默克能否靠它翻身？|默克|临床|临床试验_新浪网
默克/葛兰素史克M7824肿瘤试验再被终止 PD-L1/TGF-β双抗价值何在
二代PD-1抑制剂M7824或成肺癌治疗新选择_腾讯新闻
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional ...
惋惜？双靶点免疫治疗药M7824三期临床试验未能胜过单靶点PD-1抑制剂-MedSci.cn
惋惜？双靶点免疫治疗药M7824三期临床试验未能胜过单靶点PD-1抑制剂_腾讯新闻
惋惜？双靶点免疫治疗药M7824三期临床试验未能胜过单靶点PD-1抑制剂 - 知乎
Bintrafusp alfa (designated in previous publications as M7824) in ...
2019-02-05-m7824
新一代PD-1抑制剂M7824治疗癌症的原理是什么？【康必行海外医疗】
第二代PD-1抑制劑，總緩解率高達71.4%的雙功能性免疫新藥M7824 - 每日頭條
新一代PD-1抑制剂M7824治疗癌症的原理是什么？-康安途海外医疗
癌症治療重磅新藥M7824橫空出世！總緩解率高達71.4%！ - 每日頭條
宫颈癌临床试验招募,PD-L1和TGFβ(贝塔)双靶点药物M7824临床试验招募进行中-无癌家园
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and ...
宫颈癌竞逐丨K药一线宫颈癌OS终点达到，双抗、ADC、单抗先后获益 - 知乎
没有最好，只有更好：“闲不住”的科学家在研发新型PD-1抗体-咚咚肿瘤科
